1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
X Quarterly report pursuant to Section 13 or 15(d) of the Securities
- --- Exchange Act of 1934.
For the quarterly period ended September 30, 2000
- --- Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934.
For the transition period from ___________ to ___________.
Commission File Number
0 19777 10 1
ALLOS THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
DELAWARE 54-1655029
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
7000 NORTH BROADWAY, SUITE 400
DENVER, COLORADO 80221
(303) 426-6262
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
As of September 30, 2000, there were 22,939,740 shares of the Registrant's
Common Stock outstanding, par value $0.001 per share.
This quarterly report on Form 10-Q, including exhibits, consists of 14 pages.
The exhibit index is located on page 14.
2
ALLOS THERAPEUTICS, INC.
FORM 10-Q
INDEX
PAGE
NUMBER
------
PART I. Financial Information
ITEM 1. Financial Statements ............................................. 3
Balance Sheet --
as of September 30, 2000 (unaudited) and
December 31, 1999 ............................................ 3
Statement of Operations (unaudited) --
for the three and nine months ended September 30, 2000 and
1999 and the period from inception (September 1, 1992)
through September 30, 2000 ................................... 4
Statement of Cash Flows (unaudited) --
for the nine months ended September 30, 2000 and 1999 and
the period from inception (September 1, 1992) through
September 30, 2000 ........................................... 5
Notes to Financial Statements (unaudited) ........................ 6
ITEM 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations ............................................ 7
PART II. Other Information ..................................................... 12
ITEM 1. Legal Proceedings ................................................ 12
ITEM 2. Changes in Securities and Use of Proceeds ........................ 12
ITEM 3. Defaults Upon Senior Securities .................................. 12
ITEM 4. Submission of Matters to a Vote of Security Holders .............. 12
ITEM 5. Other Information ................................................ 12
ITEM 6. Exhibits and Reports on Form 8-K ................................. 12
SIGNATURES ..................................................................... 13
Page 2 of 14
3
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
ALLOS THERAPEUTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEET
SEPTEMBER 30, DECEMBER 31,
ASSETS 2000 1999
------------- -------------
(UNAUDITED)
Current assets:
Cash and cash equivalents $ 3,164,496 $ 2,597,884
Short-term investments 56,370,346 6,877,303
Prepaid expenses - research 529,127 223,117
Prepaid expenses - other 88,796 45,311
Other assets 5,253 185,898
------------- -------------
Total current assets 60,158,018 9,929,513
------------- -------------
Marketable securities 27,857,888 --
Property and equipment (net of accumulated depreciation of $421,576 and
$322,227, respectively) 311,713 230,360
Other assets 24,731 45,641
------------- -------------
Total assets $ 88,352,350 $ 10,205,514
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable - related parties $ 4,000 $ 8,087
Accrued expenses - research 1,426,944 768,592
Accounts payable - trade 148,312 65,123
Accrued compensation and employee benefits 133,756 224,379
Current portion of capital lease obligations 63,843 79,042
------------- -------------
Total current liabilities 1,776,855 1,145,223
Long-term portion of capital lease obligations 22,105 69,320
------------- -------------
Total liabilities 1,798,960 1,214,543
Stockholders' equity:
Convertible preferred stock, Series A: $0.001 par value, 0 and 5,000,000 shares
authorized, issued and outstanding at September 30, 2000 and December 31, 1999,
respectively (liquidation value: $6,718,107 at December 31, 1999) -- 5,000
Convertible preferred stock, Series B: $0.001 par value, 0 and 5,050,000 shares
authorized at September 30, 2000 and December 31, 1999, respectively; 0 and
5,032,500 shares issued and outstanding at September 30, 2000 and December 31, 1999,
respectively (liquidation value: $10,191,261 at December 31, 1999) -- 5,033
Convertible preferred stock, Series C: $0.001 par value, 0 and 16,610,000 shares
authorized at September 30, 2000 and December 31, 1999, respectively; 0 and
15,255,786 shares issued and outstanding at September 30, 2000 and December 31,
1999, respectively (liquidation value: $30,161,846 at December 31, 1999) -- 15,256
Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2000,
no shares issued or outstanding -- --
Common stock, $0.001 par value; 75,000,000 and 31,000,000 shares authorized
at September 30, 2000 and December 31, 1999, respectively; 22,939,740 and 2,022,138
shares issued and outstanding at September 30, 2000 and December 31, 1999,
respectively 22,940 2,022
Additional paid-in capital preferred stock -- 49,873,495
Additional paid-in capital common stock 156,607,718 7,020,291
Notes receivable - related parties (49,687) (139,687)
Accumulated deficit (61,757,972) (43,348,145)
Deferred compensation related to grant of options (8,269,609) (4,442,294)
------------- -------------
Total stockholders' equity 86,553,390 8,990,971
------------- -------------
Total liabilities and stockholders' equity $ 88,352,350 $ 10,205,514
============= =============
The accompanying notes are an integral part of these financial statements.
Page 3 of 14
4
ALLOS THERAPEUTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF OPERATIONS
(UNAUDITED)
CUMULATIVE
PERIOD FROM
SEPTEMBER 1, 1992
(INCEPTION)
THREE MONTHS ENDED NINE MONTHS ENDED THROUGH
SEPTEMBER 30, SEPTEMBER 30, SEPTEMBER 30,
2000 1999 2000 1999 2000
------------ ------------ ------------ ------------ -----------------
Operating expenses:
Research and development $ 2,024,245 $ 962,396 $ 7,904,271 $ 5,341,379 $ 30,850,158
Clinical manufacturing 958,526 193,092 2,105,370 869,423 7,270,203
General and administrative 2,103,630 418,165 11,464,656 1,206,387 18,635,389
------------ ------------ ------------ ------------ ------------
Total operating expenses 5,086,401 1,573,653 21,474,297 7,417,189 56,755,750
Loss from operations (5,086,401) (1,573,653) (21,474,297) (7,417,189) (56,755,750)
Interest and other income, net 1,482,687 34,009 3,064,470 189,487 4,610,753
------------ ------------ ------------ ------------ ------------
Net loss (3,603,714) (1,539,644) (18,409,827) (7,227,702) (52,144,997)
Dividend related to beneficial conversion
feature of preferred stock -- -- -- -- (9,612,975)
------------ ------------ ------------ ------------ ------------
Net loss attributable to common stockholders $ (3,603,714) $ (1,539,644) $(18,409,827) $ (7,227,702) $(61,757,972)
============ ============ ============ ============ ============
Net loss per common share:
Basic and diluted $ (0.16) $ (0.77) $ (1.13) $ (3.63)
============ ============ ============ ============
Weighted average common shares - basic and
diluted 22,871,795 1,997,306 16,350,444 1,989,525
============ ============ ============ ============
The accompanying notes are an integral part of these financial statements.
Page 4 of 14
5
ALLOS THERAPEUTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF CASH FLOWS
(UNAUDITED)
CUMULATIVE
PERIOD FROM
SEPTEMBER 1, 1992
NINE MONTHS ENDED (INCEPTION) THROUGH
SEPTEMBER 30, SEPTEMBER 30,
2000 1999 2000
------------- ------------- -------------------
Cash Flows From Operating Activities
Net loss $ (18,409,827) $ (7,227,702) $ (52,144,997)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization 99,349 109,096 451,371
Stock-based compensation expense 13,135,503 -- 15,504,264
Other -- -- 52,406
Changes in operating assets and liabilities:
Decrease (increase) in prepaids and other assets (147,939) (93,628) (647,906)
(Increase) decrease in interest receivable on
short-term investments (1,613,229) 80,692 (1,707,721)
Increase (decrease) in accounts payable - related parties (4,087) (113,016) 4,000
Increase (decrease) in accounts payable - research 658,352 (184,990) 1,426,944
Increase (decrease) in accounts payable - trade 83,189 (60,071) 148,312
Increase (decrease) in accrued compensation and
employee benefits (90,623) (25,671) 133,756
------------- ------------- -------------
Net cash used in operating activities (6,289,312) (7,515,290) (36,779,571)
------------- ------------- -------------
Cash Flows From Investing Activities
Acquisition of property and equipment (180,703) (17,911) (473,895)
Purchase of investments (89,348,102) (3,941,734) (137,285,280)
Proceeds from maturities of investments 13,610,400 11,786,030 54,764,767
------------- ------------- -------------
Net cash provided by (used in) investing activities (75,918,405) 7,826,385 (82,994,408)
------------- ------------- -------------
Cash Flows From Financing Activities
Principal payments under capital leases (62,414) (87,682) (336,140)
Proceeds from sale leaseback -- -- 120,492
Proceeds from stockholder loan -- -- 12,000
Repayment of stockholder loan -- -- (12,000)
Proceeds from issuance of convertible preferred stock, net
of issuance costs (2,503) (49,769) 40,283,306
Proceeds from issuance of common stock, net of issuance
costs 82,839,246 569 82,870,817
------------- ------------- -------------
Net cash provided by (used in) investing activities 82,774,329 (136,882) 122,938,475
------------- ------------- -------------
Net increase (decrease) in cash 566,612 174,213 3,164,496
Cash and cash equivalents, beginning of period 2,597,884 1,656,546 --
------------- ------------- -------------
Cash and cash equivalents, end of period $ 3,164,496 $ 1,830,759 $ 3,164,496
============= ============= =============
Supplemental Schedule of Noncash Operating and Financing
Activities:
Cash paid for interest 23,787 -- 33,787
Issuance of stock in exchange for license agreement -- -- 40,000
Capital lease obligations incurred for purchase of
property and equipment -- 2,105 422,088
Issuance of stock in exchange for notes receivable -- -- 139,687
The accompanying notes are an integral part of these financial statements.
Page 5 of 14
6
ALLOS THERAPEUTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
1. BASIS OF PRESENTATION
The accompanying unaudited financial statements of Allos Therapeutics,
Inc., referred to herein as the Company, we, us or our, have been prepared
pursuant to the rules and regulations of the Securities and Exchange Commission
("SEC"). Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to such rules and
regulations. However, the Company believes that the disclosures are adequate to
make the information presented not misleading. The unaudited financial
statements included herein have been prepared on the same basis as the annual
financial statements and reflect all adjustments, which include only normal
recurring adjustments necessary for a fair presentation in accordance with
generally accepted accounting principles. The results for the nine-month period
ended September 30, 2000 are not necessarily indicative of the results expected
for the full fiscal year. These financial statements should be read in
conjunction with the December 31, 1999 audited financial statements and the
notes thereto included in the Company's Form S-1 filed with the SEC on March 27,
2000.
The Company has not generated any revenue to date and its activities have
consisted primarily of developing products, raising capital and recruiting
personnel. Accordingly, the Company is considered to be in the development stage
at September 30, 2000 as defined in Statement of Financial Accounting Standards
No. 7, "Accounting and Reporting by Development Stage Enterprises".
2. EARNINGS PER COMMON SHARE
Basic earnings per common share is computed using the weighted average
number of common shares outstanding during the period. Diluted earnings per
common share is computed using the weighted average number of common and
potential common shares outstanding during the period. Potential common shares
consist of stock options and warrants and have been excluded from the
computation of diluted earnings per common share because their effect was
anti-dilutive.
Page 6 of 14
7
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following Management's Discussion and Analysis of Financial Condition
and Results of Operations, as well as information contained elsewhere in this
report, contains statements that constitute "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. You can identify
these statements by forward-looking words such as "may," "will," "expect,"
"intend," "anticipate," "believe," "estimate," "plan," "could," "should" and
"continue" or similar words. Actual results could differ materially from those
anticipated in these forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, those mentioned
in the discussion below and those described in the "Risk Factors" discussion of
our Registration Statement on Form S-1 filed with the Securities and Exchange
Commission. As a result, you should not place undue reliance on these
forward-looking statements. We do not intend to update or revise these
forward-looking statements to reflect future events or developments.
OVERVIEW
We are a pharmaceutical company focused on developing and commercializing
innovative small molecule drugs initially for improving cancer treatments. Our
lead product candidate is RSR13. RSR13 is a synthetic small molecule that
increases the release of oxygen from hemoglobin, the oxygen carrying protein
contained within red blood cells. We believe RSR13 can be used to improve
existing treatments for cancer and treat many diseases attributed to or
aggravated by tissue oxygen deprivation.
To date, we have devoted substantially all of our resources to research and
clinical development. We have not derived any commercial revenues from product
sales, and we do not expect to receive product revenues for at least the next
several years. We have incurred significant operating losses since our inception
in 1992 and, as of September 30, 2000, had an accumulated deficit of
$61,757,972. There can be no assurance if or when we will become profitable. We
expect to continue to incur significant operating losses over the next several
years as we continue to incur increasing research and development costs, in
addition to costs related to clinical trials and manufacturing activities. We
expect that losses will fluctuate from quarter to quarter and that such
fluctuations may be substantial. Our achieving profitability depends upon our
ability, alone or with others, to successfully complete the development of our
product candidates, and obtain required regulatory clearances and successfully
manufacture and market our future products.
RESULTS OF OPERATIONS
Expenses
Research and Development
Research and development expenses were $2,024,000 for the three months
ended September 30, 2000 compared to $962,000 for the three months ended
September 30, 1999, which represents a $1,062,000, or 110% increase. Excluding
the impact of non-cash charges (see "Non-cash
Page 7 of 14
8
Charges" below for discussion of stock compensation expense allocated to
research and development), research and development expenses increased $488,000,
or 51%. The increase was primarily due to commencement of a Phase III oncology
trial and an increase in headcount. For the nine months ended September 30, 2000
and 1999, research and development expenses were $7,904,000 and $5,341,000,
respectively. Excluding the impact of non-cash charges comprising amortization
of deferred compensation expense and stock compensation expense, research and
development expenses decreased $1,390,000, or 26%. The decrease in the nine
month period was primarily due to lower clinical trial costs resulting from the
completion of several Phase II clinical trials in oncology and cardiopulmonary
bypass.
Clinical Manufacturing
Clinical manufacturing expenses include the cost of manufacturing RSR13
for use in clinical trials and costs associated with the scale-up of
manufacturing to support commercial requirements. Clinical manufacturing
expenses were $959,000 for the three months ended September 30, 2000 compared to
$193,000 for the three months ended September 30, 1999, which represents a
$766,000, or 397% increase. For the nine months ended September 30, 2000 and
1999, clinical manufacturing expenses were $2,105,000 and $869,000,
respectively, which represents a $1,236,000 or 142% increase. The increase in
both periods was primarily related to purchasing additional drug to meet
expected clinical trial requirements associated with our Phase III oncology
trial and increased personnel cost.
General and Administrative
General and administrative expenses were $2,104,000 for the three months
ended September 30, 2000, compared to $418,000 for the three months ended
September 30, 1999. Excluding the impact of non-cash charges (see "Non-cash
Charges" below for discussion of stock compensation expense allocated to general
and administrative), general and administrative expenses increased $566,000, or
135%. For the nine months ended September 30, 2000 and 1999, general
administrative expenses were $11,465,000 and $1,206,000, respectively. Excluding
the impact of the non-cash charges, general and administrative expenses
increased $1,214,000, or 100%. The increase in both periods was the result of an
increase in headcount and additional expenses associated with becoming a public
company.
Non-cash Charges
For the three months and nine months ended September 30, 2000, we recorded
amortization of deferred stock compensation of $1,757,000 and $5,428,000,
respectively. The compensation charge resulted from granting of certain options
to employees prior to our March 2000 initial public offering with exercise
prices below the fair market value of our common stock on their respective grant
dates. Of the $1,757,000 recorded for the three months ended September 30, 2000,
$1,120,000 related to general and administrative, $573,000 related to research
and development and the remaining $64,000 related to clinical manufacturing. For
the nine months ended September 30, 2000, $3,542,000 related to general and
administrative, $1,718,000 related to research and development and $168,000
related to clinical manufacturing.
Page 8 of 14
9
For the nine months ended September 30, 2000, we recorded $7,617,000 in
stock compensation expense in connection with the forgiveness of the 1996 Notes
(as defined below) in the first quarter of 2000. Of this amount, $5,417,000
related to general and administrative and the remaining $2,200,000 related to
research and development. This compensation charge is a result of obtaining
recourse notes receivable in March 1996 (the "1996 Notes") from two officers in
the amount of $90,000 upon the officers' exercise of 558,000 stock options. The
1996 Notes accrued interest at 8% annually with interest and principal
originally due March 1998. In December 1997, the maturity dates for the 1996
Notes were extended by two years and extended by an additional year in January
2000. Upon forgiveness of the notes in March 2000, we recorded stock
compensation expense based on the difference between the fair market value of
the underlying common stock and option exercise price.
Interest and Other Income, Net
Interest income, net of interest expense, was $1,483,000 and $34,000 for
the three months ended September 30, 2000 and 1999, respectively, representing
an increase of $1,449,000, or 4,262%. For the nine months ended September 30,
2000 and 1999, net interest income was $3,064,000 and $189,000, respectively,
representing an increase of $2,875,000, or 1,521%. These increases were
primarily attributable to increased earnings from higher investment balances
resulting from the proceeds of our initial public offering of common stock
completed in March 2000.
LIQUIDITY AND CAPITAL RESOURCES
Our principal source of working capital has been private and public equity
financings as well as grant revenues and interest income.
As of September 30, 2000, we had approximately $87,393,000 in cash, cash
equivalents and investments. Net cash used in operating activities of $6,289,000
during the nine months ended September 30, 2000 resulted primarily from the net
loss for the period and a reduction in working capital. Net cash used in
operating activities of $7,515,000 during the nine months ended September 30,
1999 resulted primarily from the net loss for the period.
Net cash used in investing activities of $75,918,000 for the nine months
ended September 30, 2000, consisted primarily of purchases of investments net of
proceeds. Net cash provided by investing activities of $7,826,000 for the nine
months ended September 30, 1999, consisted primarily of proceeds from maturities
of investments, net of purchases.
Net cash provided by financing activities of $82,774,000 for the nine
months ended September 30, 2000 primarily resulted from the sale of common stock
which was offset by payments under our capital lease obligations. Net cash used
in financing activities of $137,000 for the nine months ended September 30,
1999, consisted of payments under our capital lease obligations and expenses
associated with a private placement.
Based upon the current status of our product development and
commercialization plans, we believe cash, cash equivalents and investments will
be adequate to satisfy our capital needs through at least the calendar year
2002. However, our actual capital requirements will depend on many factors,
including the status of product development; the time and cost involved in
Page 9 of 14
10
conducting clinical trials and obtaining regulatory approvals; filing,
prosecuting and enforcing patent claims; competing technological and market
developments; and our ability to market and distribute our future products and
establish new collaborative and licensing arrangements.
Our forecast of the period of time through which our financial resources
will be adequate to support our operations is a forward-looking statement that
involves risks and uncertainties, and actual results could vary materially. The
factors described above will impact our future capital requirements and the
adequacy of our available funds. We may be required to raise additional funds
through public or private financings, collaborative relationships or other
arrangements. There can be no assurance that such additional funding, if needed,
will be available on terms attractive to us, or at all. Furthermore, any
additional equity financing may be dilutive to existing stockholders and debt
financing, if available, may involve restrictive covenants. Collaborative
arrangements, if necessary to raise additional funds, may require us to
relinquish rights to certain of our technologies, products or marketing
territories. Our failure to raise capital when needed could have a material
adverse effect on our business, financial condition and results of operations.
MARKET RISK
We are exposed to certain market risks, primarily changes in interest
rates. Uncertainties that are either nonfinancial or nonquantifiable, such as
political, economic, tax, other regulatory, or credit risks, are not included in
the following assessment of our market risks.
Investments, including cash equivalents, short-term investments and
long-term marketable securities, consist of commercial paper and corporate
bonds, with maturities of up to 24 months. All investments are classified as
held-to-maturity as defined in SFAS No. 115, "Accounting for Certain Investments
in Debt and Equity Securities," and accordingly are carried at amortized cost.
Changes in interest rates could impact our anticipated interest income.
We prepared sensitivity analyses of our interest rate exposures and its
exposure from anticipated investment for fiscal 2000 and 2001 to assess the
impact of hypothetical changes in interest rates. Based on the results of these
analyses, a 10% adverse change in interest rates from the 1999 fiscal year-end
rates would not have a material adverse effect of the fair value of investments
and would not materially impact our results of operations, cash flows, or
financial condition for the next twelve months.
RISK FACTORS
In addition to the other information contained in this report, we caution
stockholders and potential investors that the following important factors, among
others, in some cases have affected, and in the future could affect, our actual
results of operations and could cause our actual results to differ materially
from those expressed in any forward-looking statements made by, on, or on behalf
of us. The following information is not intended to limit in any way the
characterization of other statements or information under other captions as
cautionary statements for such purpose. These factors include:
o Delay, difficulty, or failure to obtain regulatory approval or
clearance to market our product candidates; including delays or
difficulties in development because of insufficient proof of safety or
efficacy.
Page 10 of 14
11
o Our limited experience in conducting and managing clinical trials;
failure to conduct clinical trials in compliance with applicable
regulations and at an acceptable cost.
o The ability to obtain, maintain and enforce intellectual property
rights; the cost of acquiring in-process technology and other
intellectual property rights, either by license, collaboration or
purchase of another entity; the cost of enforcing or defending our
intellectual property rights.
o Failure of third party collaborators to conduct research and
development activities, including drug discovery and clinical testing;
conflicts of interest or priorities that may arise between us and such
third party collaborators.
o Dependence upon third parties to manufacture RSR13 bulk drug substance
and formulated drug product; failure of third parties to manufacture
RSR13 bulk drug substance or formulated drug product in compliance
with regulatory requirements and at an acceptable cost; failure of
third parties to supply sufficient quantities of RSR13 bulk drug
substance or formulated drug product for preclinical, clinical or
commercial purposes; failure to establish alternative sources of
supply of RSR13 bulk drug substance or formulated drug product.
o The ability to create sales, marketing and distribution capabilities
for our product candidates, or enter into agreements with third
parties to perform these functions;
o The ability to obtain acceptable prices or adequate levels of
reimbursement for our products from third party payors, including
government and health administration authorities and private health
insurers.
o Difficulties or high cost of obtaining adequate financing to fund
future research, development and commercialization of product
candidates.
o Competitive or market factors that may limit the use or broad
acceptance of our product candidates.
o The ability to attract and retain highly qualified management and
scientific personnel.
Page 11 of 14
12
PART II. OTHER INFORMATION
Item 1. Legal Proceedings None
Item 2. Changes in Securities and Use of Proceeds
None
Report of Use of Proceeds from Initial Public Offering in March 2000:
Aggregate offering price $90,000,000
Expenses incurred in connection with offering 7,200,000
-----------
Net offering proceeds to issuer 82,800,000
Investment in marketable securities 82,800,000
Item 3. Defaults Upon Senior Securities None
Item 4. Submission of Matters to a Vote of Security Holders None
Item 5. Other Information None
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits 27 (Financial Data Schedule)
(b) Reports on Form 8-K None
Page 12 of 14
13
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended, (the "Exchange Act") the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Date: October 27, 2000 ALLOS THERAPEUTICS, INC.
/s/ Stephen J. Hoffman
-----------------------------------
Stephen J. Hoffman, PhD, MD
President and Chief Executive
Officer
/s/ Michael E. Hart
-----------------------------------
Michael E. Hart
Chief Financial Officer and Sr.
Vice President, Operations
/s/ Paulette M. Wilson
-----------------------------------
Paulette M. Wilson
Controller
Page 13 of 14
14
INDEX TO EXHIBITS
EXHIBIT
NUMBER DESCRIPTION
- ------- -----------
27 FINANCIAL DATA SCHEDULE
Page 14 of 14